logo
Contributor: To dumbly go where no space budget has gone before

Contributor: To dumbly go where no space budget has gone before

Yahoo29-04-2025
Reports that the White House may propose nearly a 50% cut to NASA's Science Mission Directorate are both mind-boggling and, if true, nothing short of disastrous. To make those cuts happen — a total of $3.6 billion — NASA would have to close the Goddard Space Flight Center in Maryland, and cancel the mission that will bring back samples of Mars, a mission to Venus and the Nancy Grace Roman Space Telescope, which is nearly ready to launch.
Every space telescope besides the Hubble and the James Webb would be shut down. According to the American Astronomical Society, some cuts would include projects that help us understand the sun's effects on global communications, a potential national security threat.
Casey Dreier, the policy advocate for the Pasadena-based Planetary Society, says, 'This is an extinction-level event for the Earth- and space-science communities, upending decades of work and tens of billions in taxpayers' investment.'
Read more: Mars rocks are a science prize the U.S. can't afford to lose
In addition, NASA as a whole would see a 20% cut — just as we are moving forward with the Artemis program. Artemis is NASA's step-by-step 'Moon to Mars' human spaceflight campaign. Artemis II is set to launch sometime next year and will send four astronauts on a lunar fly-by, the first time humans have been in close proximity to another celestial body in more than 50 years. While it seems likely that Artemis will continue in some fashion, a 20% overall agency budget cut won't leave any part of NASA unaffected.
The president promised a 'golden age of America'; his nominee to head NASA promised a 'golden age of science and discovery.' This would be a return to the dark ages.
Taking a blowtorch to space science would also have little effect on the federal budget while setting back American leadership in space — and the inspiration it provides across political divides — by generations.
Read more: Earth 1, asteroids 0: The next generation of planetary defense takes shape at JPL
The Astronomical Society warns that our cutbacks will outsource talent 'to other countries that are increasing their investments in facilities and workforce development.' And, as Dreier points out, spacecraft would be 'left to tumble aimlessly in space' and billions wasted that have already been spent. 'Thousands of bright students across the country,' he wrote recently, 'would be denied careers in science and engineering absent the fellowships and research funds to support them.'
Here's the dollars-and-cents context. NASA's budget since the 1970s "hovers" between 1% and 0.4% of the federal discretionary spending, according to the Planetary Society's analysis, yet for every dollar spent, NASA generates $3 in the national economy. NASA's giveback was worth nearly $76 billion in economic impact in 2023, supporting more than 300,000 jobs. In California alone, NASA and its associated partners in industry and academia provide more than 66,000 jobs, more than $18 billion in economic activity and $1 billion in state tax revenue. NASA's bang-for-the-buck is astronomical, pun intended.
Cutting waste is one thing. Evisceration is another. When it comes to science — from public health to climate change — the current administration is doing the latter, not the former.
Read more: Saturn's moon looked like a snowy Utah landscape in my mind. The reality is just as compelling
Meanwhile, China continues its space ambitions, with plans for a human lunar campaign and its own 'sample return' mission to the Red Planet. For now, fortunately, the bipartisan support for NASA seems to be holding. Democrats and Republicans in Congress, led by the Planetary Science Caucus, have spoken out against this attack on NASA. And the Planetary Society has engaged thousands of passionate activists to fight this battle.
Humans yearn for connection to the universe — so we watch launches on social media, we follow the tracks of rovers on Mars and we marvel at creation in pictures transmitted from the James Webb Space Telescope. We borrow telescopes from the public library and look to the heavens.
Bending metal — the actual process of making rovers and spaceships and telescopes — drives economic activity. Fascinating results — the data from space science missions — fires the imagination.
We choose to go to space — sending humans and probes — and we pursue knowledge because curiosity is our evolutionary heritage. We explore other worlds to know them and, in doing so, we discover more about ourselves.
If you agree, let Congress know. That may be the only backstop against dumbly going where no budget has gone before.
Christopher Cokinos is a nature-and science writer whose most recent book is "Still as Bright: An Illuminating History of the Moon from Antiquity to Tomorrow."
If it's in the news right now, the L.A. Times' Opinion section covers it. Sign up for our weekly opinion newsletter.
This story originally appeared in Los Angeles Times.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Left-leaning national group is targeting these Utah legislative districts for 2026 election
Left-leaning national group is targeting these Utah legislative districts for 2026 election

Yahoo

time19 minutes ago

  • Yahoo

Left-leaning national group is targeting these Utah legislative districts for 2026 election

Members of the House of Representatives work at the Capitol in Salt Lake City on Thursday, Feb. 6, 2025. (Photo by Spenser Heaps for Utah News Dispatch) The national group Vote Save America — an online voter guide operated by the left-of-center political media company Crooked Media — is partnering with a Utah political action committee to recruit progressive candidates and target certain 'swing' legislative districts currently controlled by Republicans. Vote Save America is partnering with Elevate PAC (which is affiliated with Elevate Campaign strategies, a Utah-based political consulting firm) to 'actively recruit candidates' for the Utah Legislature ahead of the 2026 elections, according to a news release issued Tuesday. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX 'Backed by an initial $20,000 investment from Vote Save America, Elevate PAC is already recruiting candidates in key swing districts who are ready to bring new energy and leadership to the state Legislature,' the announcement said. The 'targeted' legislative districts include eight seats in the House and two in the Senate, both of which have been dominated by Republicans for decades. All but one district include areas concentrated in Salt Lake County, Utah's most populated county. They include: House District 10, currently held by Rep. Jill Koford, R-Ogden House District 26, currently held by Rep. Matt MacPherson, R-West Valley City House District 27, currently held by Rep. Anthony Loubet, R-Kearns House District 36, currently held by Rep. Jim Dunnigan, R-Taylorsville House District 39, currently held by Rep. Ken Ivory, R-West Jordan House District 42, currently held by Rep. Clinton Okerlund, R-Sandy House District 43, currently held by Rep. Steve Eliason, R-Sandy House District 44, currently held by Rep. Jordan Teuscher, R-South Jordan Senate District 18, currently held by Sen. Dan McCay, R-Riverton Senate District 19, currently held by Senate Majority Leader Kirk Cullimore, R-Draper Vote Save America is the political advocacy arm of Crooked Media, a media company founded by Jon Favreau, Jon Lovett and Tommy Vietor, who were all aides to former President Barack Obama, according to Influence Watch. The company hosts podcasts including Pod Save America and Lovett or Leave It, and encourages listeners to support progressive policies and vote for Democratic candidates. The national group is 'betting on Utah's shifting political landscape,' Tuesday's news release said. 'Long considered safely Republican, Utah is showing signs of becoming competitive in the coming years.' Utah during the 2024 presidential election remained solidly red. About 59.4% voted for President Donald Trump and 37.8% voted for former Vice President Kamala Harris, according to election results. Utah's 2024 election is certified, capping off a 'status quo' year for Republican dominance Democrats have a stronghold in Utah's capital of Salt Lake City and some areas including in Salt Lake County, but they have struggled to gain traction in other parts of the state. 'Utah is uniquely positioned for change,' Shaniqua McClendon, vice president of politics for Crooked Media, said in a prepared statement. 'It's the youngest state in the country, one of the fastest-growing, and the most college-educated red state. No state in the nation has moved further to the left over the past 20 years than Utah. There's an independent streak here that national politics has ignored for too long.' Gabi Finlayson, principal at Elevate PAC, said the partnership with Vote Save America 'gives us the resources and reach to go find the people who've been shut out or ignored — people with real stakes in their communities, not just the usual insiders.' 'This initial $20,000 is going directly toward identifying and vetting potential candidates,' Finlayson said. 'We're grateful to have a national partner that sees Utah the way we do: a real opportunity to build something different, right now. If you've never run for office before, if you've felt written off or overlooked, this is your chance.' Utah Republican Party Chairman Rob Axson did not immediately return a request for comment about the group's targeting of legislative seats currently controlled by Republicans. SUPPORT: YOU MAKE OUR WORK POSSIBLE

NYC Board of Elections to certify GOP Council primary despite fraud claims, dead voters
NYC Board of Elections to certify GOP Council primary despite fraud claims, dead voters

Yahoo

time19 minutes ago

  • Yahoo

NYC Board of Elections to certify GOP Council primary despite fraud claims, dead voters

The Board of Elections is set to certify the results of a Republican primary for a Brooklyn-based City Council seat on Tuesday even as allegations of voter fraud have loomed over the contest — infuriating the Democratic candidate in the race who believes matters should be put on hold until the irregularities can be investigated. Kayla Santosuosso, who won last month's Democratic primary for the 47th Council District, told the Daily News she has this week pleaded with the Board of Elections to delay certifying the results of the GOP primary in the 47th because of the voter fraud suspicions. Santosuosso's push comes after the board last week announced it had discovered 22 'potentially fraudulent' ballots cast in the GOP primary — a finding that could've been significant as ardent pro-Trump candidate George Sarantopoulos leads the race by just 32 votes over Richie Barsamian, the Brooklyn Republican Party's chairman. The board says it has tossed those votes, but also revealed last week it is not invalidating at least two additional ballots cast in the names of individuals who are dead, though it did say it referred those findings to the Brooklyn district attorney's office, which has launched an investigation. Despite the ballot irregularities and Santosuosso's request for a pause, Vinny Ignizio, the BOE's deputy executive director, confirmed Tuesday morning that the board would later Tuesday certify the 47th GOP primary, saying his team has 'completed a comprehensive and transparent review of all valid ballots, including a full hand count.' 'The outcome of the race has remained consistent at every stage. In accordance with New York State Election Law, all valid votes have been properly counted,' Ignizio said. 'Our responsibility now is to certify the results and proceed with preparations for the general election in November. Any specific allegations of fraud will be handled appropriately by the district attorney's office.' Santosuosso, voicing concern there could be more fraudulent ballots in the mix that haven't been detected yet, blasted the board's decision. 'The Board of Elections is certifying an election that includes ballots from dead people,' she said. 'If Republicans actually believe their own hype about election integrity, they'd be standing with me demanding a real investigation before this election is certified.' The campaigns of Sarantopoulos and Barsamian did not immediately return requests for comment. The 47th Council District, which is currently represented by term-limited Councilman Justin Brannan, spans Bay Ridge, Coney Island and some other neighboring southern Brooklyn areas. The district is expected to be one of the most competitive Council contests in November's general election, with many southern Brooklyn neighborhoods trending more conservative in recent years. Santosuosso is the chief counsel in Brannan's government office and has his backing in her bid to succeed him.

Celcuity shares triple on late-stage results for breast cancer therapy
Celcuity shares triple on late-stage results for breast cancer therapy

Yahoo

time36 minutes ago

  • Yahoo

Celcuity shares triple on late-stage results for breast cancer therapy

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biotechnology firm Celcuity said Monday a late-stage trial testing its experimental breast cancer therapy in combination with other drugs succeeded, positioning the Minneapolis-based company to submit an approval application to the Food and Drug Administration later this year. Treatment involving the biotech's drug, called gedatolisib, significantly reduced the risk of disease progression or death in patients with a certain kind of advanced breast tumor that continued to grow despite initial therapy. Researchers observed this progression-free survival benefit in both patients given a 'doublet' drug combination including gedatolisib and a 'triplet' combination. In a statement, Celcuity said the trial achieved 'several new milestones' in testing of treatments for breast cancer that's positive for hormone receptors but negative for another protein called HER2. Co-principal investigator Sara Hurvitz, head of the hematology and oncology division at the University of Washington's Department of Medicine, called the results 'potentially practice-changing' in the company's statement. With results in hand, Celcuity plans to file in the fourth quarter for FDA approval. Shares in the company tripled in early trading Monday, before settling back to trade higher by almost 200%. The share price gain inflated Celcuity's market value to about $1.5 billion. Celcuity's study enrolled patients with HR+, HER2- tumors that tested negative for common mutations in a gene called PI3KCA. In one group, the company paired gedatolisib with Pfizer's Ibrance and AstraZeneca's Faslodex, which is available as generic fulvestrant. Treatment with the triplet reduced the risk of disease progression by 76% compared to fulvestrant alone. Progression-free survival reached a median of 9.3 months in the triplet group versus just 2 months for those on fulvestrant. Given with just fulvestrant, gedatolisib treatment reduced progression by 67%, leading to a median progression-free survival of 7.4 months. The company said patient discontinuation rates due to treatment-related adverse events was lower in this study than in Phase 3 trials for approved drug combinations for this patient population. Full data from the trial will be presented at an upcoming medical conference later this year. Andrew Berens, an analyst at Leerink Partners, wrote in a client note Monday that the data 'are likely clinically meaningful across multiple subgroups' and provide rationale to use Celcuity's drug as a second-line breast cancer treatment. 'The 7.3 and 5.4-months incremental improvement in median PFS relative to fulvestrant for the gedatolisib regimens are potentially paradigm-shifting results,' claimed Igor Gorbatchevsky, chief medical officer of Celcuity, in a statement. Other approved drug combinations in the second-line setting are supported by data showing lower median progression-free survival, of about two to four months, compared to the doublet and triplet regimens using gedatolisib. Celcuity expects to have data for gedatolisib in breast cancer patients with PIK3CA mutations by the end of this year. Recommended Reading Full Arvinas, Pfizer data confirm potential, limits of 'Protac' drug in breast cancer Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store